---
title: "Policy Pulse — Modi / India — 22 Jul 2026"
ticker: "ONGC:OIL:IOC:BPCL:HPCL:MRPL:SUNPHARMA:LUPIN:CIPLA:DRREDDY:AUROPHARMA:ZYDUSLIFE:BAJAJ-AUTO:TVSMOTOR:NESTLEIND:HUL:TATACONSUM:BANDHANBNK"
date: "2026-07-22"
tags: ["policy-pulse","modi","india","pharma","oil","hormuz","earnings","market-roundup"]
summary: "Nifty below 24,000 on Brent 5, IOCs halt Iraq oil loadings due to Hormuz (ONGC gains, IOC/BPCL/HPCL pressured). Trump generic drug tariff crushes Sun Pharma, Lupin, Cipla. Nestlé, Bajaj Auto shine on stellar Q1. Bandhan Bank -19% on RoA cut."
model: "deepseek-chat"
---

## 📊 Market Context — Indian Markets on July 22, 2026

Indian equity markets extended losses for a third consecutive session. **Sensex fell 715 pts (0.92%) to 76,755; Nifty fell 191 pts (0.79%) to 23,996** — slipping below the psychological 24,000 mark for the first time in 9 sessions. The downturn was driven by Brent crude surging above $95 amid escalating US-Iran conflict in the Strait of Hormuz, and Trump's generic drug tariff announcement.

### Key Market Data
- **Rupee:** Fell 32 paise to **96.56/USD** (pressured by oil + strong dollar)
- **Gold:** ₹144,615/10g (+1,732); **Silver:** ₹225,159/kg (+1,380)
- **India VIX:** Surged 5.6% (elevated anxiety)
- **Brent:** $94.33 (+3.7%); **WTI:** $87.28 (+3.5%)
- **Nifty Midcap 100:** -1.09%; **Nifty Smallcap 100:** -1.53%
- **Advance-Decline:** Sharply negative (~2:1, 403 of Nifty 500 stocks in red)

### Sector Performance

| Sector | Change | Key Driver |
|--------|--------|------------|
| Nifty FMCG | **+0.65%** 🟢 | Nestlé Q1 beat (PAT +48% YoY); defensive buying |
| Nifty Auto | **+0.18%** 🟢 | Bajaj Auto 52-week high on stellar Q1 |
| Nifty Oil & Gas | -0.6% 🔴 | Crude spike hurts OMCs, but ONGC gains |
| Nifty Metal | -0.48% 🔴 | Global slowdown fears + input cost concerns |
| Nifty Energy | -0.3% 🔴 | Mixed sector performance |
| Nifty Infra | -0.85% 🔴 | Broad selling |
| Nifty Consumer Durables | -0.86% 🔴 | Demand concerns |
| Nifty Pharma | **-1.3%** 🔴 | Trump generic drug tariff bombshell; 2% of Nifty Pharma knocked off |
| Nifty Private Bank | -1.4% 🔴 | Bandhan Bank -19% on RoA guidance cut; HDFC Bank -8% in 3 days |
| Nifty IT | **-1.5%** 🔴 | Infosys results due Jul 23; pre-earnings profit booking |
| Nifty PSU Bank | -1.8% 🔴 | SBI -1.86%; sector-wide weakness |
| Nifty Bank | -1.2% 🔴 | Axis Bank -1.96%, ICICI -1.6% |
| Nifty Realty | **-2.6%** 🔴 | Highest sectoral loss; interest rate + funding cost fears |
| Nifty Media | **-2.68%** 🔴 | Worst sector; ad revenue slowdown fears |

---

### Top Nifty 50 Gainers & Losers

| Gainers | Change | Losers | Change |
|---------|--------|--------|--------|
| Bajaj Auto | **+5.92%** | InterGlobe Aviation | -3.66% |
| Nestlé India | +3.24% | Dr. Reddy's Labs | -2.16% |
| Tata Consumer | +1.43% | Jio Financial | -2.14% |
| Eternal | +1.01% | Infosys | -2.00% |
| ONGC | +0.74% | Axis Bank | -1.96% |
| Power Grid | +0.80% | SBI | -1.86% |
| HUL | +0.68% | Max Healthcare | -1.85% |
| NTPC | +0.53% | UltraTech Cement | -1.85% |

---

### 🌍 Global Spillover Stories Affecting India

#### 🔴 IOC & MRPL Halt Iraq Oil Loadings
**IOC** and **MRPL** have suspended crude oil loadings from Iraq due to mounting security risks in the Strait of Hormuz. IOC abandoned plans to load a supertanker from Basrah Oil Terminal. This is a direct, real-world impact of the Hormuz crisis on Indian energy security.

| Stock | Impact | Reason |
|-------|--------|--------|
| IOC | 🔴 Negative | Forced to source costlier spot crude; disruption to Iraq supply (traditionally 10-15% of India's crude imports) |
| MRPL | 🔴 Negative | Dependent on Persian Gulf crude; supply disruption hurts refining margins |
| BPCL | 🔴 Negative | Also sources Iraq crude; alternative sourcing costs higher |
| HPCL | 🔴 Negative | Rising crude hurts under-recoveries; government may delay price pass-through |
| ONGC | 🟢 Positive | Higher crude oil realization for domestically produced oil; substitution demand benefits |
| OIL | 🟢 Positive | Higher crude price environment benefits upstream E&P companies |

#### 🔴 Trump Generic Drug Tariff — Indian Pharma Stocks Crushed
Trump announced a **phased generic drug tariff** via Truth Social on July 22:
- Zero tariffs until Aug 1, 2028 (2-year grace)
- 100% tariff from Aug 1, 2028
- 200% tariff from Aug 1, 2029

Indian pharma exports to the US are ~$10B, and India supplies **40% of US generic drugs** by volume. While the 2-year window provides breathing room, the long-term trajectory is clearly negative.

| Stock | Impact | Reason |
|-------|--------|--------|
| SUNPHARMA | 🔴 Negative | 30%+ US revenue exposure; large generic portfolio; fell 1.91% |
| LUPIN | 🔴 Negative | ~40% US revenue; generic-heavy; led pharma decliners |
| CIPLA | 🔴 Negative | Major US generics presence; -1.56% on the day |
| DRREDDY | 🔴 Negative | Strong US generics footprint; fell 2.16% |
| AUROPHARMA | 🔴 Negative | 50%+ US revenue; largest US generic manufacturing footprint among Indian cos |
| ZYDUSLIFE | 🔴 Negative | Growing US generics book; tariff headwind |
| ALEMBIC | 🔴 Negative | US generics dependent; Nifty 500 decliner |
| GLENMARK | 🔴 Negative | US generics exposure; fell 1-3% |
| GLAND | 🔴 Negative | Injectable generics; could be tariff target despite complexity |
| BIOCON | 🔴 Negative | Biosimilars exposed to U.S. market; Malaysia-based manufacturing doesn't help |
| MARKSANS | 🔴 Negative | Down 7-13% (sharpest); small-cap generic exposed |

**Note:** The **2-year grace period** means NO immediate earnings impact. However, long-term structural threat to the Indian generic pharma business model. Companies with **local U.S. manufacturing** (Aurobindo, Dr. Reddy's, Lupin, Cipla, Zydus) may be better positioned to adapt. **Alkem** and **Torrent** (fully India-dependent) face the highest risk.

#### 🟢 Nestlé India & Bajaj Auto — Earnings Bright Spots
**Nestlé India:** Q1 consolidated net profit surged **48% YoY to ₹959 cr**; revenue ₹6,378 cr. Stock +3.24%.

**Bajaj Auto:** Q1 net profit +42% YoY to ₹2,983 cr; revenue +37%. Hit 52-week high (+5.92%). Record sales and exports. TVS Motor also strong (+3-4.5%) — Q1 PAT +51% YoY.

| Stock | Impact | Reason |
|-------|--------|--------|
| NESTLEIND | 🟢 Positive | Exceptional Q1 beat (PAT +48%); strong rural/urban demand |
| BAJAJ-AUTO | 🟢 Positive | Record Q1 (PAT +42%); export recovery + strong domestic; 52-week high |
| TVSMOTOR | 🟢 Positive | Stellar Q1 (PAT +51%); best-ever quarterly revenue & volume |
| ETERNAL | 🟢 Positive | Q1 profit ₹92 cr; stock +1.01% |

#### 🔴 Bandhan Bank — RoA Guidance Cut Spooks Investors
Bandhan Bank reported 37% PAT growth to ₹1,037 cr in Q1, but cut FY27 RoA guidance due to rising deposit costs. Stock **plunged ~19%**.

| Stock | Impact | Reason |
|-------|--------|--------|
| BANDHANBNK | 🔴 Negative | RoA guidance cut signals margin pressure; deposit costs rising |

#### 🔴 IOC, MRPL Halt Iraq Loadings
As noted above — Indian refiners halt Iraq oil loadings due to Hormuz risk. Direct energy security impact.

---

## 📋 Summary of Stock Signals (India Focus)

| Category | Direction | Key Tickers |
|----------|-----------|-------------|
| Crude-sensitive (Hormuz) | 🟢 BUY ONGC, OIL | ONGC, OIL |
| Crude-sensitive (Refiners) | 🔴 SELL | IOC, BPCL, HPCL, MRPL |
| Pharma Generic (Trump tariff) | 🔴 SELL | SUNPHARMA, LUPIN, CIPLA, DRREDDY, AUROPHARMA |
| Pharma with US plants (adaptive) | 🟡 HOLD | AUROPHARMA, DRREDDY, LUPIN, CIPLA, ZYDUSLIFE |
| Auto (earnings winners) | 🟢 BUY | BAJAJ-AUTO, TVSMOTOR |
| FMCG (defensive, earnings beat) | 🟢 BUY | NESTLEIND, HUL, TATACONSUM |
| Banking (rate-sensitive, earnings risk) | 🔴 SELL | BANDHANBNK, SBI, AXISBANK |
| IT (pre-earnings; Infosys Jul 23) | 🟡 Neutral | INFY, TCS, HCLTECH, WIPRO |